EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An activator of voltage-gated K + channels Kv1.1 as a therapeutic candidate for episodic ataxia type 1

Ilenio Servettini iD, Giuseppe Talani iD, Alfredo Megaro iD, Maria Dolores Setzu iD, Francesca Biggio, Michelle Briffa iD, Luca Guglielmi, Nicoletta Savalli, Francesca Binda, Francis Delicata, Gilles Bru-Mercier iD, Neville Vassallo iD und 9 weitere

Proceedings of the National Academy of Sciences · 2023-08 · 120 (31)

DOI: 10.1073/pnas.2207978120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 24.07.2023. Verfasst von Ilenio Servettini und 20 weiteren Autor:innen. Beteiligte Einrichtung: Section of Physiology, Department of Medicine, University of Perugia, Perugia 06123, Italy. Hauptthemen laut MEDLINE: Myokymia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, HHS | NIH | National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loss-of-function mutations in the KCNA1 (Kv1.1) gene cause episodic ataxia type 1 (EA1), a neurological disease characterized by cerebellar dysfunction, ataxic attacks, persistent myokymia with painful cramps in skeletal muscles, and epilepsy. Precision medicine for EA1 treatment is currently unfeasible, as no drug that can enhance the activity of Kv1.1-containing channels and offset the functional defects caused by KCNA1 mutations has been clinically approved. Here, we uncovered that niflumic acid (NFA), a currently prescribed analgesic and anti-inflammatory drug with an excellent safety profile in the clinic, potentiates the activity of Kv1.1 channels. NFA increased Kv1.1 current amplitudes by enhancing the channel open probability, causing a hyperpolarizing shift in the voltage dependence of both channel opening and gating charge movement, slowing the OFF-gating current decay. NFA exerted similar actions on both homomeric Kv1.2 and heteromeric Kv1.1/Kv1.2 channels, which are formed in most brain structures. We show that through its potentiating action, NFA mitigated the EA1 mutation–induced functional defects in Kv1.1 and restored cerebellar synaptic transmission, Purkinje cell availability, and precision of firing. In addition, NFA ameliorated the motor performance of a knock-in mouse model of EA1 and restored the neuromuscular transmission and climbing ability in Shaker (Kv1.1) mutant Drosophila melanogaster flies ( Sh 5 ). By virtue of its multiple actions, NFA has strong potential as an efficacious single-molecule-based therapeutic agent for EA1 and serves as a valuable model for drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyokymiaAnimalsMiceDrosophila melanogasterAtaxiaDrosophilaKv1.2 Potassium Channel

Stichwörter der Autor:innen

Kv1.1(KCNA1)Kv1.2(KCNA2)OMIM160120episodic ataxia type 1niflumic acid

Substanzen

Kv1.2 Potassium Channel

Autor:innen und Institutionen

  • Section of Physiology, Department of Medicine, University of Perugia, Perugia 06123, Italy.
  • Institute of Neuroscience, National Research Council, Monserrato 09042, Italy.
  • Department of Biomedical Sciences, University of Cagliari, Monserrato 09042, Italy.
  • Department of Life and Environmental Sciences, University of Cagliari, Monserrato 09042, Italy.
  • Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida MSD2080, Malta.
  • Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.

ORCID-Profile: Ilenio Servettini, Giuseppe Talani, Alfredo Megaro, Maria Dolores Setzu, Michelle Briffa, Gilles Bru-Mercier, Neville Vassallo, Vittorio Maglione, Ruben J Cauchi, Paola Imbrici, Maria Cristina D'Adamo, Mauro Pessia

Förderung

  • NIGMS NIH HHS
  • HHS | NIH | National Institute of General Medical Sciences

Zitieren

APA

Servettini, I., Talani, G., Megaro, A., Setzu, M. D., Biggio, F., Briffa, M., Guglielmi, L., Savalli, N., Binda, F., Delicata, F., Bru-Mercier, G., Vassallo, N., Maglione, V., Cauchi, R. J., Di Pardo, A., Collu, M., Imbrici, P., Catacuzzeno, L., D'Adamo, M. C., …, & Pessia, M. (2023). An activator of voltage-gated K + channels Kv1.1 as a therapeutic candidate for episodic ataxia type 1. Proceedings of the National Academy of Sciences, 120(31). https://doi.org/10.1073/pnas.2207978120

Vancouver

Servettini I, Talani G, Megaro A, Setzu MD, Biggio F, Briffa M, et al. An activator of voltage-gated K + channels Kv1.1 as a therapeutic candidate for episodic ataxia type 1. Proceedings of the National Academy of Sciences. 2023;120(31). doi:10.1073/pnas.2207978120

BibTeX
@article{Servettini2023,
  author = {Servettini, Ilenio and Talani, Giuseppe and Megaro, Alfredo and Setzu, Maria Dolores and Biggio, Francesca and Briffa, Michelle and Guglielmi, Luca and Savalli, Nicoletta and Binda, Francesca and Delicata, Francis and Bru-Mercier, Gilles and Vassallo, Neville and Maglione, Vittorio and Cauchi, Ruben J and Di Pardo, Alba and Collu, Maria and Imbrici, Paola and Catacuzzeno, Luigi and D'Adamo, Maria Cristina and Olcese, Riccardo and Pessia, Mauro},
  title = {An activator of voltage-gated K + channels Kv1.1 as a therapeutic candidate for episodic ataxia type 1},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {31},
  doi = {10.1073/pnas.2207978120}
}
Kostenlos starten →